Table of Contents
Overview
New York, NY – May 12, 2025 – Global Thyroid Ablation Devices Market size is expected to be worth around US$ 418.3 Million by 2033 from US$ 168.8 Million in 2023, growing at a CAGR of 9.5% during the forecast period 2024 to 2033.
The global Thyroid Ablation Devices market is witnessing growing interest due to the increasing incidence of thyroid disorders, particularly thyroid cancer and benign thyroid nodules. These devices are used in minimally invasive procedures that eliminate abnormal thyroid tissue using techniques such as radiofrequency ablation (RFA), microwave ablation (MWA), and laser ablation. Such procedures are emerging as effective alternatives to conventional surgery, offering reduced recovery times, fewer complications, and preservation of thyroid function.
Rising preference for outpatient treatment and growing awareness of minimally invasive solutions are supporting the adoption of these devices across hospitals and specialty clinics. According to the American Cancer Society, over 44,000 new cases of thyroid cancer are expected in the United States in 2024, highlighting the need for early and effective intervention methods.
Technological advancements in image-guided ablation systems and increased investment in healthcare infrastructure are also enhancing procedural safety and precision. North America currently holds the largest market share, while the Asia-Pacific region is projected to experience the fastest growth due to increasing regulatory approvals and healthcare modernization.
As healthcare providers prioritize patient comfort and cost-effective interventions, thyroid ablation devices are gaining momentum as a standard approach in thyroid nodule management. The market outlook remains positive, driven by clinical demand, innovation, and expanding access to advanced care.
Key Takeaways
- In 2023, the global thyroid ablation devices market was valued at USD 8 million, and it is projected to reach USD 418.3 million by 2033, expanding at a compound annual growth rate (CAGR) of 9.5% during the forecast period.
- By Product Type, the market is categorized into microwave and radiofrequency devices. In 2023, radiofrequency devices dominated the segment, accounting for a 63.5% share of the market.
- By Technology, the market is divided into thermal and non-thermal approaches. The thermal segment emerged as the major contributor, with a market share of 71.2% in 2023.
- By Application, the market is segmented into cancer and nodules. The cancer application held the largest share, generating 58.9% of total revenue in 2023.
- By End-use, the market is classified into hospitals, cancer specialty centers, ambulatory surgical centers, and others. Hospitals led the segment, contributing 52.4% of the revenue.
- By Region, North America was the leading market in 2023, holding a dominant 41.2% share of the global revenue.
Segmentation Analysis
- By Product Type Analysis: In 2023, the radiofrequency segment led the thyroid ablation devices market with a 63.5% share, driven by its effectiveness in treating benign and malignant nodules. As a minimally invasive and outpatient procedure, it appeals to both patients and clinicians. The rising prevalence of thyroid disorders, combined with technological advancements, favorable reimbursement, and growing awareness of non-surgical options, continues to support strong adoption of radiofrequency ablation across healthcare settings.
- By Technology Analysis: The thermal ablation technology segment held a dominant 71.2% market share in 2023, supported by increasing demand for non-surgical thyroid treatments. This method uses heat to target abnormal tissue while preserving healthy areas, reducing complications. Its alignment with outpatient care trends, shorter recovery periods, and strong clinical evidence enhances provider confidence. Adoption is further supported by technological improvements in precision and outcomes, especially in aging populations where thyroid disorders are more prevalent.
- By Application Analysis: The cancer application segment commanded a 58.9% revenue share in 2023, driven by the rising incidence of thyroid cancer and demand for less invasive treatments. Many early-stage patients now prefer ablation over surgery, influenced by quicker recovery and fewer risks. Improved targeting precision, government cancer initiatives, and growing awareness of alternative therapies contribute to segment growth. Favorable clinical outcomes position ablation as a viable primary or adjunct therapy in thyroid cancer management.
- By End-use Analysis: In 2023, the hospitals segment dominated with a 52.4% revenue share, benefiting from their role as primary centers for thyroid disorder treatment. Hospitals are equipped with advanced imaging and ablation tools and staffed with skilled professionals, ensuring safe and effective procedures. Increased diagnosis rates, infrastructure development in emerging regions, and strategic collaborations with device manufacturers further drive adoption. The push for minimally invasive care and outpatient services also reinforces hospital demand for thyroid ablation technologies.
Market Segments
By Product Type
- Microwave
- Radiofrequency
By Technology
- Thermal
- Non-thermal
By Application
- Cancer
- Nodules
By End-use
- Hospitals
- Cancer Specialty Centers
- Ambulatory Surgical Centers
- Others
Regional Analysis
North America Leads the Thyroid Ablation Devices Market
In 2023, North America accounted for the largest revenue share of 41.2% in the thyroid ablation devices market. The growth is driven by the increasing incidence of thyroid cancer and the rising preference for minimally invasive treatment methods. According to the American Cancer Society, the U.S. is expected to report approximately 44,020 new cases of thyroid cancer in 2024, including 31,520 in women and 12,500 in men, along with an estimated 2,170 related deaths.
This rising burden has elevated the demand for safe, non-surgical alternatives such as ablation procedures. Continuous advancements in radiofrequency and microwave ablation technologies have improved treatment precision and outcomes, leading to wider adoption among healthcare providers.
The region also benefits from a well-developed healthcare infrastructure, strong clinical awareness, and a growing shift toward outpatient and cost-effective care solutions. These factors collectively support the region’s dominant position in the global market.
Asia Pacific to Register the Fastest Growth Rate
The Asia Pacific region is projected to witness the highest compound annual growth rate (CAGR) during the forecast period. This growth is attributed to regulatory support, increasing awareness of non-surgical thyroid treatments, and the rising burden of thyroid disorders across the region.
A notable development includes the July 2023 approval of a Class III microwave ablation disposable needle by China’s National Medical Products Administration (NMPA), developed by Baird Medical for thyroid nodule treatment. Such approvals are accelerating the use of advanced ablation technologies in clinical settings.
Moreover, expanding healthcare infrastructure in countries such as China and India, along with growing disposable income and increased healthcare spending, is making minimally invasive treatments more accessible. The region is expected to see strong demand for thyroid ablation devices as healthcare systems advance and awareness of early intervention improves.
Emerging Trends
- Minimally Invasive Techniques: Thermal ablation methods, such as radiofrequency ablation (RFA), have gained prominence for treating benign thyroid nodules. These techniques allow for the targeted destruction of nodule tissue while preserving surrounding healthy thyroid tissue. The procedure is typically performed on an outpatient basis, reducing hospital stays and recovery times.
- Application in Low-Risk Thyroid Cancers: Recent studies have explored the use of thermal ablation in managing low-risk papillary thyroid microcarcinomas (PTMCs). This approach offers a less invasive option for patients who may not be ideal candidates for surgery, aligning with a broader trend toward therapeutic de-escalation in oncology.
- Integration into Clinical Guidelines: As evidence supporting the efficacy and safety of thyroid ablation grows, professional medical societies are beginning to incorporate these techniques into clinical practice guidelines. This integration facilitates broader adoption and standardization of care across healthcare settings.
Use Cases
- Treatment of Benign Thyroid Nodules: Thyroid ablation is effective in reducing the size of benign nodules that cause compressive symptoms or cosmetic concerns. Studies have reported significant volume reductions, improving patient comfort and quality of life.
- Management of Autonomously Functioning Thyroid Nodules: For nodules that produce excess thyroid hormones leading to hyperthyroidism, ablation offers a targeted treatment that can normalize hormone levels without the need for lifelong medication.
- Alternative to Surgery for Low-Risk Thyroid Cancer: In select cases of low-risk thyroid cancers, such as PTMCs, ablation provides a non-surgical option that minimizes risks associated with thyroidectomy, including vocal cord paralysis and hypothyroidism.
Conclusion
In conclusion, the global thyroid ablation devices market is experiencing robust growth driven by rising thyroid disorder prevalence, increasing demand for minimally invasive treatments, and technological advancements in ablation techniques. With procedures such as radiofrequency and microwave ablation gaining clinical acceptance, patients benefit from reduced recovery times, fewer complications, and preserved thyroid function.
North America leads in market share due to advanced healthcare infrastructure, while Asia Pacific is poised for the fastest growth owing to regulatory support and expanding medical access. As clinical guidelines evolve and awareness increases, thyroid ablation devices are expected to become a standard option in thyroid disease management.
